Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3658_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •2 Principles of radiofrequency and microwave tumor ablation
- •Cooling in microwave ablation
- •Pulsed RF application
- •Operator and technique
- •Choice of applicator
- •Overlapping techniques
- •Introduction
- •Biology of heating
- •Radiofrequency ablation
- •Microwave ablation
- •Energy-deposited technology
- •Multitine applicators
- •Internally cooled electrodes
- •Perfused electrodes
- •Ancillary procedures
- •Combination therapies
- •Combining RF with transarterial chemoembolization
- •Combining RF with chemotherapy
- •Combining RF ablation with radiation
- •Patient selection
- •Conclusion
- •References
- •3 Principles of irreversible electroporation
- •Introduction
- •Numerical simulations
- •Clinical considerations
- •Clinical experience
- •Conclusion
- •References
- •4 Principles of high-intensity focused ultrasound
- •Introduction
- •History
- •Ablation
- •Hyperthermia
- •Thermal dose concept
- •Cavitation
- •Histotripsy
- •Microstreaming
- •HIFU system technology
- •Ultrasound guidance
- •MRI guidance
- •HIFU devices
- •Clinical applications
- •Prostate
- •Breast
- •Liver
- •Bone
- •Emerging applications
- •Targeted drug delivery
- •Blood–brain barrier disruption
- •Conclusion
- •References
- •5 Principles of tumor embolotherapy and chemoembolization
- •Tumor embolotherapy
- •General indications
- •Embolic materials
- •Gelfoam
- •Coils
- •Absolute ethanol
- •Microspheres
- •Pre-embolization evaluation
- •Roadmap and superselective arteriography
- •Chemoembolization
- •Basic principle
- •Chemotherapeutic agents used for chemoembolization
- •Lipiodol chemoembolization
- •Subsegmental chemoembolization
- •Drug-eluting bead TACE (DEB-TACE)
- •References
- •6 Principles of radioembolization
- •Introduction
- •Mechanism of radioembolization
- •Radioembolic material
- •Indications and contraindications
- •Imaging considerations
- •Base and follow-up cross-sectional imaging
- •Localization imaging (nuclear medicine imaging)
- •Determining treatment dosage (activity)
- •(Y-90) SIR-Sphere
- •(Y-90) TheraSphere
- •Microcatheters
- •(Y-90) SIR-Sphere
- •(Y-90) TheraSphere
- •Radiation safety considerations
- •Patient release
- •Radiation safety considerations for cases involving surgery
- •Radiation safety considerations in case of autopsy, burial, or cremation
- •References
- •Background
- •Regional delivery of the drug leads to increased local concentration
- •Increased local concentration leads to increased therapeutic response
- •Regional delivery of a drug leads to decreased systemic exposure
- •5-Fluorouracil
- •Irinotecan
- •Oxaliplatin
- •Hepatic artery combination chemotherapy administration
- •Hepatic intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI)
- •Therapeutic monoclonal antibodies
- •Future research
- •Regional therapy pharmacology appendix
- •Pharmacology appendix
- •References
- •Introduction
- •Imaging for procedure planning
- •Imaging for device delivery
- •Advances in real-time imaging
- •Three-dimensionality
- •Navigation
- •Robotics
- •Combining best systemic chemotherapy with best HAI strategy
- •Open access to the patient
- •Radiation exposure
- •Intraprocedural monitoring
- •Imaging for therapy assessment
- •Summary
- •References
- •9 Novel developments in MR assessment of treatment response after locoregional therapy
- •Anatomic biomarkers
- •The volumetric approach
- •Conclusion
- •References
- •10 Assessment and triage of hepatocellular carcinoma
- •Summary
- •Introduction
- •Assessment of hepatocellular carcinoma
- •Diagnostic criteria
- •Clinical staging
- •Triage of hepatocellular carcinoma
- •Liver transplantation
- •Surgical resection
- •Image-guided ablation
- •Transarterial treatment
- •Systemic treatment
- •Conclusion
- •References
- •11 Image-guided ablation of hepatocellular carcinoma
- •Introduction
- •Very-early-stage hepatocellular carcinoma
- •Early-stage hepatocellular carcinoma
- •Conclusion
- •References
- •Celiac trunk anatomy
- •Normal celiac trunk anatomy and variations
- •Celiac stenosis or occlusion
- •Hepatic artery anatomy
- •Intrahepatic variations in branching segmental hepatic arteries
- •Non-hepatic arteries arising from hepatic arteries
- •Pancreaticoduodenal arteries
- •Extrahepatic collateral arteries
- •Anatomy of extrahepatic collateral arteries
- •Inferior phrenic arteries
- •Internal mammary arteries
- •Intercostal and lumbar arteries
- •Omental arteries
- •Adrenal arteries
- •Renal and renal capsular arteries
- •Gastric arteries
- •Colic branches
- •Transcatheter management of extrahepatic collateral arteries
- •References
- •Background
- •Patient selection and contraindications for TACE and DEB-TACE
- •Technique
- •Follow-up and evaluation of response to treatment
- •Clinical outcome
- •Combination therapies
- •Conclusion and outlook
- •References
- •Patient selection
- •Technique
- •Dosimetry
- •Adverse events and toxicities
- •Clinical outcomes
- •References
- •15 Image-guided therapy of intrahepatic cholangiocarcinoma
- •Curative therapies
- •Percutaneous ablation
- •Non-curative therapies
- •Chemoembolization
- •Radioembolization
- •Multidisciplinary approach
- •References
- •Introduction
- •Indications
- •Contraindications
- •Ablation modalities
- •Radiofrequency ablation
- •Cryoablation
- •Microwave ablation
- •Irreversible electroporation
- •Laser-induced interstitial thermotherapy
- •Discussion
- •References
- •17 Assessment, triage, and chemoembolization for colorectal liver metastases
- •Assessment of the patient with liver metastases
- •Triage of patients with liver metastases
- •Resection
- •Ablation
- •Intra-arterial chemoinfusion
- •Systemic therapy
- •Chemoembolization
- •Patient selection for chemoembolization
- •Chemoembolization regimens
- •“Conventional” cocktails
- •Drug-eluting microsphere platforms
- •Technical aspects of chemoembolization
- •Loading
- •Technique for drug-eluting microsphere embolization
- •Delivery endpoints
- •Outcomes with drug-eluting microspheres
- •Summary
- •References
- •18 Radioembolization for colorectal liver metastases
- •Introduction
- •Patient presentation
- •Preimplantation workup procedure
- •Treatment process
- •Dosimetry and dose calculation
- •TheraSphere
- •SIR-Spheres
- •Postprocedural care and follow-up
- •Postprocedure considerations
- •Postembolization syndrome (20–30%)
- •CT/PET evaluation of tumor response
- •Radioembolization combined with second- or third-line chemotherapy
- •Conclusion
- •References
- •19 Assessment, triage, and liver-directed therapies for neuroendocrine tumor metastases
- •Terminology
- •Demographics and epidemiology
- •Diagnosis
- •Prognosis
- •Multidisciplinary triage of neuroendocrine neoplasms
- •Systemic therapies
- •Surgical management
- •Image-guided therapy
- •Tumor ablation
- •Hepatic arterial therapy
- •Conclusion
- •References
- •20 Preoperative portal vein embolization
- •Mechanisms of liver regeneration
- •Rate of liver regeneration
- •Standard approaches
- •Additional approaches
- •PVE in conjunction with transarterial therapies
- •Extent of embolization
- •Embolic materials
- •Complications
- •General indications
- •General contraindications
- •Underlying liver disease
- •High-dose chemotherapy
- •Conclusion
- •References
- •Photodynamic therapy
- •Radiotherapy
- •References
- •Clinical overview
- •Staging
- •Diagnosis
- •Treatment options
- •Surgery
- •Percutaneous techniques
- •Radiofrequency ablation
- •Background
- •Histology of RFA
- •Microwave ablation
- •Background
- •Histology
- •Cryoablation
- •Background
- •Histology of cryoablation
- •Indications for percutaneous ablation
- •Patient factors
- •Preablation imaging
- •Adjunctive procedures
- •Technique
- •Anesthesia
- •Modality for guidance
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Adjacent structures
- •Postprocedure follow-up
- •Complications
- •Treatment of metastatic disease
- •Surgical and RFA options
- •Medical therapies
- •Conclusion
- •References
- •23 Embolotherapy in the management of renal cell carcinoma
- •Introduction
- •Basic concepts
- •Embolization technique
- •Preoperative embolization
- •Radical nephrectomy
- •Partial nephrectomy
- •Postoperative embolization
- •Palliative embolization
- •Complications
- •Conclusion
- •References
- •Physics of ablation therapy
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Performing ablation therapy
- •Patient selection
- •Procedure
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Imaging follow-up
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Comparison of thermal ablation techniques
- •Applications and outcomes for thoracic ablation
- •Palliation
- •Conclusion
- •References
- •Introduction
- •Indications for treatment
- •Preprocedural imaging
- •Contraindications to ablation treatment
- •RFA technique
- •RFA pain palliation outcomes
- •Cryoablation technique
- •Cryoablation pain palliation outcomes
- •Emerging technologies
- •Summary
- •References
- •26 Cementoplasty and musculoskeletal interventions
- •Introduction
- •Indications
- •Contraindications
- •Technique
- •Postprocedural care and follow-up
- •Current bone cement properties and future directions
- •Percutaneous sacroplasty, osteoplasty, and advance hybrid stabilization techniques
- •Summary
- •References
- •27 Prostate ablations
- •Introduction
- •Patient selection
- •Cancer detection and treatment guidance
- •Patient selection
- •Targeting strategies
- •Image guidance for prostate ablation
- •Ultrasound guidance
- •MR guidance
- •Computed tomography guidance
- •Positron emission tomography guidance
- •Prostate ablation techniques
- •High-intensity focused ultrasound
- •Cryoablation
- •Other techniques
- •Postprocedure evaluation
- •Complications and outcomes
- •Local control
- •Conclusion
- •Acknowledgments
- •References
- •Indications
- •Rationale
- •Technique
- •Catheter positioning
- •Contraindications
- •Results
- •Port/catheter placement
- •Chemotherapy
- •Description
- •Indications
- •Preoperative assessment
- •Catheter tip location
- •Update on vein thrombosis prophylaxis and treatment
- •Catheter-related infection
- •References
- •29 Palliative care and symptom management
- •Palliative care and communication with cancer patients
- •Communication with cancer patients
- •Prognostication
- •Medical symptom management
- •Pain
- •Non-opioid analgesics
- •Opioid analgesics
- •Adjuvant analgesics
- •Bone metastases
- •Nausea and vomiting
- •Constipation
- •Constitutional symptoms
- •Ascites
- •Psychiatric symptoms
- •Depression
- •Anxiety
- •Summary
- •References
- •Introduction
- •Celiac plexus neurolysis
- •Anatomy
- •Technique
- •Positioning and approach
- •Antecrural
- •Retrocrural
- •Outcomes
- •Complications
- •Superior hypogastric neurolysis
- •Anatomy
- •Technique
- •Positioning and approach
- •Outcomes
- •Complications
- •Ganglion impar neurolysis
- •Anatomy
- •Technique
- •Outcomes
- •Complications
- •References
- •Introduction
- •Management of ascites
- •Diuretics and sodium restriction
- •Large-volume paracentesis
- •Permanent indwelling catheters
- •Pigtail or Cope-type loop catheter
- •PleurX and Asept catheters
- •Peritoneal Port-A-Catheters
- •Thoracentesis
- •Chest drainage catheters
- •Pigtail catheters
- •Tunneled catheters
- •Summary of recommendations and guidelines
- •References
- •Index

Chapter2:Radiofrequency and microwave tumor ablation
tumor tissues between sessions. e goal of multiple treatmentsistocreatealarge,contiguoussphericalablativevolume.
However, giventhegeometryoftryingtoobtainalargecompletesphericalablativezone with smaller spheres,signicant
overlapofpreviouszonesisnecessaryforcompleteablation.
59,60
Alternatively, aligningablations“endtoend”wouldresultin
multipleareasofuntreatedtumor.
Combining RF with transarterial chemoembolization
ere are several potential advantages with combining RF
and TACE.is includes combined two-hit cytotoxic eects
ofexposuretonon-lethal low-levelhyperthermiainperiablational tumor and combination chemotherapy.Alterationsin
tumorperfusioncan potentiatethe eects of either RF abla-
Ancillary procedures
A major consideration of energy-based thermal ablation is
prevention of injury to nearby, non-target structures.1 As
such,several strategies havebeen devisedtoseparatecritical
non-targettissuesfromtheablationzone.
Onekeytechniqueis“hydrodissection,”inwhichuidis
injected through a separately introduced hollow-bore needletocreateseparationbetweenimportanttissues(e.g.,diaphragmorbowel)andtheablationzone.Fluidswithlowion
content,suchas5%dextroseinwater,shouldbeusedasthey
forceRFcurrentawayfrom protected tissues and decrease
theincidenceofburns.Notably,0.9%salineshouldnotbe
used, as this ionic solution actually increases RF current
61
ow.
isconcepthasalsodevelopedtoutilizeinjectionofair
(e.g., “pneumodissection”),creation of articial pneumothoraxor ascites,ormechanicaldisplacementwithballooncatheters,inplaceofuid,toseparatenon-targetedtissuesfromthe
ablationzone.
Otherancillaryproceduresincludetheapplicationofexternalwarmingorcoolingbagsforoverlyingskinprotection,utilizationofthermalballoonsforcontrollingsurroundingtissue
temperatures,andintraluminalperfusiontoprotectnon-target
structures (e.g., renal pelvicalyceal, ureteral, and bile duct
protection).
1
Combination therapies
Withfurtherlong-termfollow-upofpatientsundergoingablationtherapy, there has been an increased incidence of detectionofprogressivelocaltumorgrowthforalltumortypesand
sizesdespiteinitialindicationsofadequatetherapy,suggesting
thatthereareresidualfociofviable,untreateddiseaseinasubstantial,butunknown,numberofcases.10Strategiesthatcan
increasethe completenessoftumordestructionwithuniform
eradicationofall malignant cells, evenforsmall tumors, are
needed.Hence,investigatorshavesoughttoimproveresultsby
combiningthermal ablationwith therapies such as radiation
andchemotherapy.
62,63
Combination therapies incorporate cytotoxic or chemotherapeuticagentsadministeredinconjunctionwith ablation
to induce a synergistic eect.1 Potential advantages include
improvedtumorcytotoxicityandreducedresiduallocaltumor
atthetreatmentmargin,creationofamorecompleteareaof
tumordestructionbyllinginuntreatedgapswithintheablationzone,andequivalenttumor destruction with a concomitantreductionin duration or course oftherapy(e.g., in the
timetotreatalargertumor,orrequirementfor fewer repeat
sessions).
tionthroughpre-ablationembolizationof tumor vasculature
or TACE with postablation peripheral hyperemia increasingbloodowfor TACE.Finally,performingTACErst can
improvetumorvisualization(throughintratumoraliodizedoil
deposition)forRFablation.
64
Several studies using combination therapy have reported
increases in ablation size and increased treatment ecacy
withcombinationRF/TACE,particularlyastheprimarytreatmentoflarge(>5cm)unresectabletumors.Forexample,Yang
et al. treated 103 patients with recurrent unresectable hepatocellular carcinoma aer hepatectomy, and reported lower
intrahepaticrecurrenceandlonger3-yearsurvivalcompared
to either therapy alone.65 e potentialbenetof combining
RFwith TACEforsmall(< 3 cm) tumors remainsless clear,
as a recent meta-analysis of randomized controlled studies
reported no signicantsurvival benet for combination RF/
TACEoverRFalone.66Tailoringtreatmenttoeachindividual
caseremainsimportant,aseachmodalitycanbeusedsequentiallytoeliminateanyresidualdiseaseremainingaertheinitialprimarytherapy.Notably,thequalityoflife,asdetermined
by socio-family well-being and functional well-being scores,
isalsosuperiorinpatientsreceivingbothchemoembolization
and RF ablation,a reection of liver function, tumor recurrence,andcomplications.
67
Combining RF with chemotherapy
Combiningthermalablation(predominantlyusing RF-based
systems)withchemotherapy(either free or contained within
liposomes),whetherthrough directinjection,intravenous,or
intravascular/intra-arterialadministration,increasestheoverallvolumeoftumornecrosisandintratumoraldrugaccumulation.62eseeectsoccurpreferentiallyintheperipheralzone
of hyperemia surrounding the central zone of ablation, and
havebeenconrmedinlargeranimaltumormodels,dierent
tumorandtissuetypes,fordierentchemotherapeuticagents,
andinapilotclinicalstudyinprimaryandsecondaryhepatic
malignancies.
inmostcasestoencompassperitumoralliver,andenabledthe
destruction of the dicult-to-treat 0.5–1-cm “ablative marg i n”.68InonepilotclinicalstudybyGoldbergetal.,RFablation
combined with intravenous liposomal doxorubicin resulted
in more complete tumor treatment and ablative margin.
Additionally, combinedRFandliposomalchemotherapycan
potentiallyovercomelimitationsimposed bytumorororgan
environment,suchasbloodow.
eunderlyingmechanismsofthissynergyaremultifactorial.Improvedintratumoraldrugdelivery occurs with use of
aliposomalcarrier(withincreasedcirculationtime,andwith
“thermosensitiveliposome”types,increaseddrugrelease)and
62,68
Inclinicalcases,thetreatmenteectextended
68,69
9

Section II:Principles of image-guided therapies
the well-documented vasculareects of sublethal hyperthermia (including vascular dilatationand increased endothelial
permeability)intheperipheraltreatmentzone.70Additionally,
thecytotoxiceectsofthechemotherapyagentcombinedwith
theheat-inducedreductionincellularreparativemechanisms
toincrease apoptosis.71 Finally,studiessuggestthatthereare
independent heat-related cytotoxic eects of the liposome
itself.71 is preliminary success with combination therapies
maybeaugmentedbythedevelopmentofnewtargetingvehicles,includingseveralpolymer-basedtemperature-dependent
deliverysystemscurrentlyunderinvestigation.
72
behindtheseandthebiophysiologyofin-vivotissueheatingis
requiredtoavoidthemanypotentialpitfallsinperformingoptimalthermalablation.Wehaveprovidedabasicoverviewofthe
basicprinciplesofRFandmicrowaveablation,focusedonthree
main elements, including: (1) biology of heating; (2) RF and
microwave technology; and (3) operator expertise and technique.Successfultumorablationisabalancebetweenobtaining
completetumordestructionwhile minimizingdamagetosurroundingnormalparenchyma,andisembeddedinanappreciationandunderstandingofthesethreeinterweavingelements.
Althoughmultiplemodicationshavealreadybeendevel-
oped within the technology of RF and microwave ablation,
Combining RF ablation with radiation
Investigatorshave begun exploringcombinationRF ablation
andradiationtherapy,withpromisingresults.Previousdatain
theliteraturehavedemonstratedincreasedtumordestruction
with external-beam radiation therapy and low-temperature
hyperthermia.73 Experimental animal studies have demonstratedincreasedtumornecrosis,reducedtumorgrowth,and
improvedanimalsurvivalwithcombinedtherapywhencomparedtoeithertherapyalone.
63,74
Preliminaryclinical studies
in primary lungmalignancies conrm the synergistic eects
ofthese therapies.6A potentialcauseforsynergyincludesthe
sensitizationof thetumortosubsequentradiationdueto the
increased oxygenation resulting from hyperthermia-induced
increasedbloodowtothetumor.75Anotherpossiblemechanism,whichhasbeenseeninanimaltumormodels,isaninhibitionofradiation-inducedrepairandrecoveryandincreased
free-radical formation.71Immunohistochemicalstainingaer
RF ablation, combined with external-beam radiation, has
demonstratedanincreasein markers of oxidative and nitrosativestress.74 Futureworkis needed toidentify the optimal
temperatureforablationandoptimalradiationdose,aswellas
themosteective methodofadministeringradiationtherapy
(external-beam radiation therapy, brachytherapy, or yttrium
microspheres),onanorgan-by-organbasis.
Patient selection
Perhaps the most important variable to have the greatest
impactonresultsistheinterplaybetweenoperatorandpatient
selection. Given the need to achieve completeeradicationof
all target tumor cells, the argument for combining several
modalitiestoachievecompletetumorcelldeath–similartothe
multidisciplinaryapproach,includingsurgery,radiation,and
chemotherapy,thatisusedforthetreatmentofmostsolidcancers–cannotbeoverstated.Approachingeachcaseandindividualtumorwiththegoalofusingwhateveroptionsareavailable
within the interventional armamentarium willlikelyprovide
thehighestclinicalyield.Severalfactorsshouldbetakeninto
considerationwhenplanning combinationtherapysuch that
treatmentistailoredtoeachcase.eseincludetumorbiology,
tumorsizeandnumber,andtumoraccessibility/visibility.
Conclusion
ereisnoonerightwaytoperformRFandmicrowaveablation, yet a fundamental knowledge of the basic principles
future directions will emphasize a better understanding of
tumorbiologyinordertoalterlocaltissueinteractionscoupled
with ancillary procedures and combination and concurrent
therapies,suchasantiangiogenetics,embolization,chemotherapeutics,andradiation.
References
1. AhmedM,SolbiatiL,BraceCL,etal.Image-guidedtumor
ablation:Standardizationofterminologyandreporting
criteria–a10-yearupdate.Radiology2014;273:241–260.
2. SolbiatiL,IeraceT,CovaL,etal.Ten-yearexperiencein
nonsurgicaltreatmentof“intermediate”hepatocellular
carcinomaincirrhoticpatients:Long-termsurvivalandcauses
ofdeath.Radiology2006;241:359.
3. LivraghiT,SolbiatiL,MeloniMF,etal.Treatmentof
focallivertumorswithpercutaneousradio-frequency
ablation:complicationsencounteredinamulticenterstudy.
Radiology2003;226:441–451.
4. GillamsAR,LeesWR.Five-yearsurvivalfollowing
radiofrequencyablationofsmall,solitary,hepaticcolorectal
metastases.J Vasc Interv Radiol2008;19:712–717.
5. GervaisDA,McGovernFJ,ArellanoRS,etal.Renalcell
carcinoma:clinicalexperienceandtechnicalsuccesswith
radio-frequencyablationof42tumors.Radiology2003;
226:417–424.
6. DupuyDE,DiPetrilloT,GandhiS,etal.Radiofrequency
ablationfollowedbyconventionalradiotherapyformedically
inoperablestageInon-smallcelllungcancer.Chest2006;
129:738–745.
7. CallstromAR,AtwellTD,CharboneauJW,etal.Painful
metastasesinvolvingbone:percutaneousimage-guided
cryoablation–prospectivetrialinterimanalysis.Radiology
2006;241:572–580.
8. Dodd3rdGD,SoulenMC,KaneRA,etal.Minimallyinvasive
treatmentofmalignanthepatictumors:atthethresholdofa
majorbreakthrough.Radiographics2000;20:9–27.
9. ShimadaK,SakamotoY,EsakiM,etal.Roleofthewidthof
thesurgicalmargininahepatectomyforsmallhepatocellular
carcinomaseligibleforpercutaneouslocalablativetherapy.Am J
Surg2008;195:775–781.
10. LivraghiT,MeloniF,GoldbergSN,etal.Hepatocellular
carcinoma:radiofrequencyablationofmediumandlarge
lesions.Radiology2000;214:761–768.
11. Dodd3rdGD,FrankMS,AribandiM,etal.Radiofrequency
thermalablation:computeranalysisofthesizeofthethermal
injurycreatedbyoverlappingablations.AJR Am J Roentgenol
2001;177:777–782.
10

Chapter2:Radiofrequency and microwave tumor ablation
12. ChenMH,YangW,YanK,etal.Largelivertumors:protocol
forradiofrequencyablation,anditsclinicalapplicationin
110patients–mathematicalmodel,overlappingmode,and
electrodeplacementprocess.Radiology2004;232:260–271.
13. GervaisDA,McGovernFJ,ArellanoRS,etal.Radiofrequency
ablationofrenalcellcarcinoma:part1.Indications,results,
androleinpatientmanagementovera6-yearperiod
andablationof100tumors.AJR Am J Roentgenol2005;
185:64–71.
14. LencioniR,CrocettiL,CioniR,etal.Responseto
radiofrequencyablationofpulmonarytumours:aprospective,
intention-to-treat,multicentreclinicaltrial(theRAPTURE
study).Lancet Oncol2008;9:621–628.
15. SchrammW,YangD,HaemmerichD.Contributionof
directheating,thermalconductionandperfusionduring
radiofrequencyandmicrowaveablation.Conf Proc IEEE Eng
Med Biol Soc2006;1:5013–5016.
16. SeegenschmiedtM,BradyL,SauerR.Interstitial
thermoradiotherapy:reviewontechnicalandclinicalaspects.
Am J Clin Oncol1990;13:352–363.
17. LarsonT,BostwickD,CorciaA.Temperature-correlated
histopathologicchangesfollowingmicrowavethermoablationof
obstructivetissuesinpatientswithbenignprostatichyperplasia.
Urology1996;47:463–469.
18. ZevasN,KuwayamaA.Pathologicanalysisofexperimental
thermallesions:comparisonofinductionheatingand
radiofrequencyelectrocoagulation.J Neurosurg1972;
37:418–422.
19. GoldbergSN,GazelleGS,ComptonCC,etal.Treatment
ofintrahepaticmalignancywithradiofrequency
ablation:radiologic–pathologiccorrelation.Cancer2000;
88:2452–2463.
20. MertynaP,DewhirstMW,HalpernE,etal.Radiofrequency
ablation:theeectofdistanceandbaselinetemperatureon
thermaldoserequiredforcoagulation.Int J Hyperthermia2008;
24:550–559.
21. LubnerMG,BraceCL,HinshawJL,etal.Microwavetumor
ablation:mechanismofaction,clinicalresultsanddevices.J
Vasc Interv Radiol2010;21:192–203.
22. BraceCL.Radiofrequencyandmicrowaveablationoftheliver,
lung,kidney,andbone:whatarethedierences?Curr Probl
Diagn Radiol2009;38:135–143.
23. YuNC,LuDS,RamanSS,etal.Hepatocellular
carcinoma:microwaveablationwithmultiplestraightandloop
antennaclusters–pilotcomparisonwithpathologicndings.
Radiology2006;239:269–275.
24. LuDS,RamanSS,LimanondP,etal.Inuenceoflarge
peritumoralvesselsonoutcomeofradiofrequencyablationof
livertumors.J Vasc Interv Radiol2003;14:1267–1274.
25. GoldbergSN,HahnPF,HalpernEF,etal.Radiofrequencytissue
ablation:eectofpharmacologicmodulationofbloodowon
coagulationdiameter.Radiology1998;209:761–769.
26. HorkanC,AhmedM,LiuZ,etal.Radiofrequency
ablation:eectofpharmacologicmodulationofhepaticand
renalbloodowoncoagulationdiameterinaVX2tumor
model.J Vasc Interv Radiol2004;15:269–274.
27. HakimeA,Hines-PeraltaAU,PeddyH.Combinationof
radiofrequencyablationwithantiangiogenictherapyfortumor
ablationecacy:studyinmice.Radiology2007;244:464–470.
28. MostafaEM,GanguliS,FaintuchS,etal.Optimalstrategies
forcombiningtranscatheterarterialchemoembolizationand
radiofrequencyablationinrabbitVX2hepatictumors.J Vasc
Interv Radiol2008;19:1740–1748.
29. LiuZ,LoboSM,HumphriesS,etal.Radiofrequencytumor
ablation:insightintoimprovedecacyusingcomputer
modeling.AJR Am J Roentgenol2005;184:1347–1352.
30. GoldbergSN,AhmedM,GazelleGS,etal.Radiofrequency
thermalablationwithadjuvantsalineinjection:eectof
electricalconductivityontissueheatingandcoagulation.
Radiology2001;219:157–165.
31. MiaoY,NiY,YuJ,etal.Acomparativestudyonvalidationof
anovelcooled-wetelectrodeforradiofrequencyliverablation.
Invest Radiol2000;35:438–444.
32. YangD,ConverseMC,MahviDM,etal.Measurementand
analysisoftissuetemperatureduringmicrowaveliverablation.
IEEE Trans Biomed Eng2007;54:150–155.
33. BraceCL,LaesekePF,SampsonLA,etal.Microwaveablation
withasinglesmall-gaugetriaxialantenna:invivoporcineliver
model.Radiology2007;242:435–440.
34. WolfEJ,GrandDJ,MachanJT,etal.Microwaveablationof
lungmalignancies:eectiveness,CTndings,andsafetyin
50patients.Radiology2008;247:871–879.
35. WrightAS,SampsonLA,WarnerTF,etal.Radiofrequency
versusmicrowaveablationinahepaticporcinemodel.
Radiology2005;236:132–139.
36. WangY,SunY,FengL,etal.Internallycooledantennafor
microwaveablation:resultsinexvivoandinvivoporcinelivers.
Eur J Radiol2008;67:357–361.
37. HaemmerichDG,etal.Adevicethatallowsformultiple
simultaneousradiofrequency(RF)ablationsinseparatedareas
oftheliverwithimpedance-controlledcool-tipprobes:an
ex-vivofeasibilitystudy.Radiology2002;225:242.
38. SolbiatiL,IeraceT,GoldbergSN.PercutaneousUS-guided
RFtissueablationoflivermetastases:long-termfollow-up.
Radiology1997;202:195–203.
39. GoldbergSN,GazelleGS,DawsonSL,etal.Tissueablation
withradiofrequencyusingmultiprobearrays.Acad Radiol1995;
2:670–674.
40. deBaereT,DenysA,WoodBJ,etal.Radiofrequencyliver
ablation:experimentalcomparativestudyofwater-cooledversus
expandablesystems.AJR Am J Roentgenol2001;176:187–192.
41. MiaoY,NiY,YuJ,etal.Anexvivostudyonradiofrequency
tissueablation:increasedlesionsizebyusingan
“expandable-wet”electrode.Eur Radiol2001;11:1841–1847.
42. AppelbaumL,SosnaJ,PearsonR,etal.Algorithmoptimization
formultitinedradiofrequencyablation:comparativestudyinex
vivoandinvivobovineliver.Radiology2010;254:430–440.
43. ShibataT,ShibataT,MaetaniY,etal.Radiofrequencyablation
forsmallhepatocellularcarcinoma:prospectivecomparisonof
internallycooledelectrodeandexpandableelectrode.Radiology
2006;238:346–353.
44. GoldbergSN,SolbiatiL,HahnPF,etal.Large-volumetissue
ablationwithradiofrequencybyusingaclustered,internally
cooledelectrodetechnique:laboratoryandclinicalexperience
inlivermetastases.Radiology1998;209:371–379.
45. ShockSA,MeredithK,WarnerTF,etal.Microwaveablation
withloopantenna:invivoporcinelivermodel.Radiology2004;
231:143–149.
11

Section II:Principles of image-guided therapies
46. DesingerK,SteinT,MuellerGJ,etal.Interstitialbipolar
RF-thermotherapytherapybyplanningbycomputersimulation
andMRI-monitoring–anewconceptforminimallyinvasive
procedures.Proc SPIE1999;3249:147–160.
47. RitzJP,LehmannKS,IsbertC,etal.In-vivoevaluation
ofanovelbipolarradiofrequencydeviceforinterstitial
thermotherapyoflivertumorsduringnormalandinterrupted
hepaticperfusion.J Surg Res2006;133:176–184.
48. McGahanJP,GuWZ,BrockJM,etal.Hepaticablationusing
bipolarradiofrequencyelectrocautery.Acad Radiol1996;
3:418–422.
49. Hines-PeraltaA,HollanderCY,SolazzoS,etal.Hybrid
radiofrequencyandcryoablationdevice:preliminaryresultsin
ananimalmodel.J Vasc Interv Radiol2004;15:1111–1120.
50. GoldbergSN,GazelleGS,SolbiatiL,etal.Radiofrequencytissue
ablation:increasedlesiondiameterwithaperfusionelectrode.
Acad Radiol1996;3:636–644.
51. LorentzenT.Acooledneedleelectrodeforradiofrequency
tissueablation:thermodynamicaspectsofimproved
performancecomparedwithconventionalneedledesign.
Acad Radiol1996;3:556–563.
52. LivraghiT,GoldbergSN,MontiF,etal.Saline-enhanced
radiofrequencytissueablationinthetreatmentofliver
metastases.Radiology1997;202:205–210.
53. AhmedM,LoboSM,WeinsteinJ,etal.Improvedcoagulation
withsalinesolutionpretreatmentduringradiofrequency
tumorablationinacaninemodel.J Vasc Interv Radiol2002;
12:717–724.
54. LencioniR,CioniD,CrocettiL,etal.Earlystagehepatocellular
carcinomainpatientswithcirrhosis:long-termresultsof
percutaneousimage-guidedradiofrequencyablation.Radiology
2005;234:961–967.
55. DupuyD,GoldbergSN.Image-guidedradiofrequencytumor
ablation:challengesandopportunities–partII.J Vasc Interv
Radiol2001;12:1135–1148
56. GoldbergSN,SteinM,GazelleGS,etal.Percutaneous
radiofrequencytissueablation:optimizationofpulsed-RF
techniquetoincreasecoagulationnecrosis.J Vasc Interv Radiol
1999;10:907–916.
57. LeeJr.FT,HaemmerichD,WrightAS,etal.Multipleprobe
radiofrequencyablation:pilotstudyinananimalmodel.J Vasc
Interv Radiol2003;14:1437–1442.
58. WangX,SofocleousCT,ErinjeriJP,etal.Marginsizeisan
independentpredictoroflocaltumorprogressionaerablation
ofcoloncancerlivermetastases.Cardiovasc Interv Radiol2013;
36:166–175.
59. GoldbergSN,DupuyEE.Image-guidedradiofrequencytumor
ablation:challengesandopportunities–partI.J Vasc Interv
Radiol2001;12:1021–1032.
60. KimSK,RhimH,KimYS,etal.Radiofrequencythermal
ablationofhepatictumors:pitfallsandchallenges.Abdom
Imaging2005;30:727–733.
61. LaesekePF,SampsonLA,Winter3rdTC,etal.Useof
dextrose5%inwaterinsteadofsalinetoprotectagainst
inadvertentradiofrequencyinjuries.AJR Am J Roentgenol2005;
184:1026–1027.
62. AhmedM,GoldbergSN.Combinationradiofrequencythermal
ablationandadjuvantIVliposomaldoxorubicinincreases
tissuecoagulationandintratumouraldrugaccumulation.Int J
Hyperthermia2004;20:781–802.
63. HorkanC,DalalK,CoderreJA,etal.Reducedtumorgrowth
withcombinedradiofrequencyablationandradiationtherapy
inaratbreasttumormodel.Radiology2005;235:81–88.
64. BraceCL,SampsonLA,HinshawJL,etal.Radiofrequency
ablation:simultaneousapplicationofmultipleelectrodes
viaswitchingcreateslarger,moreconuentablationsthan
sequentialapplicationinalargeanimalmodel.J Vasc Interv
Radiol2009;20:118–124.
65. YangW,ChenMH,WangMQ,etal.Combinationtherapyof
radiofrequencyablationandtransarterialchemoembolizationin
recurrenthepatocellularcarcinomaaerhepatectomycompared
withsingletreatment.Hepatol Res2009;39:231–240.
66. WangW,ShiJ,XieWF.Transarterialchemoembolizationin
combinationwithpercutaneousablationtherapyinunresectable
hepatocellularcarcinoma:ameta-analysis.Liver Int2010;
30:741–749.
67. WangYB,ChenMH,YanK,etal.Qualityoflifeaer
radiofrequencyablationcombinedwithtranscatheterarterial
chemoembolizationforhepatocellularcarcinoma:comparison
withtranscatheterarterialchemoembolizationalone.Qual Life
Res2007;16:389–397.
68. GoldbergSN,KamelIR,KruskalJB,etal.Radiofrequency
ablationofhepatictumors:increasedtumordestructionwith
adjuvantliposomaldoxorubicintherapy.AJR Am J Roentgenol
2002;179:93–101.
69. GoldbergSN,GimanGD,LukyanovAN,etal.Percutaneous
tumorablation:increasednecrosiswithcombined
radio-frequencyablationandintravenousliposomal
doxorubicininaratbreasttumormodel.Radiology2002;
222:797–804.
70. ChenQ,KrolA,WrightA,etal.Tumormicrovascular
permeabilityisakeydeterminantforantivasculareectsof
doxorubicinencapsulatedinatemperaturesensitiveliposome.
Int J Hyperthermia2008;24:475–482.
71. SolazzoS,AhmedM,Schor-BardachR,etal.Liposomal
doxorubicinincreasesradiofrequencyablation-inducedtumor
destructionbyincreasingcellularoxidativeandnitrative
stressandacceleratingapoptoticpathways.Radiology2010;
255:62–74.
72. BaeY,BureshRA,WilliamsonTP,etal.Intelligentbiosynthetic
nanobiomaterialsforhyperthermiccombinationchemotherapy
andthermaldrugtargetingofHSP90inhibitorgeldanamycin.
J Control Release2007;122:16–23.
73. AlganO,FosmireH,HynynenK,etal.Externalbeam
radiotherapyandhyperthermiainthetreatmentofpatientswith
locallyadvancedprostatecarcinoma.Cancer2000;89:399–403.
74. SolazzoS,MertynaP,PeddiH,etal.RFablationwithadjuvant
therapy:comparisonofexternalbeamradiationandliposomal
doxorubicinonablationecacyinananimaltumormodel.Int
J Hyperthermia2008;24:560–567.
75. MayerR,Hamilton-FarrellMR,vanderKleijAJ,etal.
Hyperbaricoxygenandradiotherapy.Strahlenther Onkol2005;
181:113–123.
12

Chapter
Principles of irreversible electroporation
3
Govindarajan Srimathveeravalli and Stephen B. Solomon
Introduction
Electroporation is a phenomenon where cells exposed to a
strongexternalelectricelddevelopnano-scaleporesintheir
plasmamembrane.Typically,theporesresealoncetheexternalelectriceldisremovedandthecellcontinuesfunctioning
normally.However, ifthenumberorsizeofporesformedin
the membraneexceeds a certainthreshold,thecell is unable
torepair thepores,even aerremovaloftheexternalelectric
eld.iseect has been termedirreversibleelectroporation
(IRE). IRE may be considered a non-thermal ablation technique, as cell death is largely due to electroporation-related
factors and is not contingent on sustained changes in temperature.However,this does notcompletelyprecludeheating
ofthe treatedtissue,as Jouleheating-induceddamagetotissueduringIREhasbeenseentooccurwithina2–3-mmzone
adjacentto the probes.1 e largely non-thermalmechanism
ofcelllysismakesIREanattractiveoptionforthetreatmentof
tumorsthatarecontraindicatedforestablishedthermalablationtechniques.AsIREablationseemsunaectedbyvariations
intissueperfusionandbiologicalheat-sinkeects,ithasbeen
usedtotreathypervasculartumorsandlesionsadjacenttolarge
bloodvessels2(Figure3.1).Unlikethermalablationtechniques,
whichcandenatureproteinsandcompletelydestroycollagenousstructureswithintheablationzone,ablationwithIREhas
been observed to spare the extracellular matrix within the
treatedregions.3is has allowed the safeapplication of IRE
totreattumorsabuttingthebileductortherectuminpatients4
(Figure3.1).
IREpresentsanewclinicalparadigmfortheplanningand
delivery of image-guided ablations. Unlike thermal ablation
techniques,wheretheablationzoneiscenteredonasingleablationprobe,treatmentdeliveryusingIREis typically planned
betweentwomonopolarneedleelectrodes(Figure3.2). Small
variationsinthegeometryofprobeplacementcansignicantly
aect the size and shape of the resulting eective ablation
zone,aectingthevolumeoftissuethatundergoesdestruction
(Figure 3.3). e strongelectric elds used for IRE ablation
caninduceneuromuscularactivationandaect physiological
functionsthataresensitivetoelectrical energy.erefore,use
ofIREinpatientshasspecialanesthesiarequirements,includingtheuseofadeepparalyticagenttoreducecurrent-induced
neuromuscularstimulation.IREhastobedeliveredwithelectrocardiogram(ECG)gating toavoidventricular tachycardia,
arrhythmia, and other cardiac eects.5 Finally, there is limitedinformationon best clinical practices fortheuseofIRE,
withlimitedknowledgeonimagingndingsthatwouldallow
treatmentfollow-upandconrmationoftherapeutic ecacy
following ablation. erefore, it is crucial that the physician
using IRE for tumor ablation have a rm understanding of
thebiophysicalmechanismsunderlyingIREoftissue,andthe
potentialimpactthateachtreatmentparametercanhaveonthe
clinicaloutcomes.
Pulse parameters and impactonIRE
Livingcellsusedierencesinionicconcentrationsofintra-and
extracellularuidtoestablishanelectricpotentialacrosstheir
plasma membrane. is transmembrane potential can vary
dependingontheactivityorfunctionofthecell,andtypically
rangesfrom–35to–70mV.Whencellsareexposedtoanexternalelectriceld, theirtransmembranepotentialaltersrapidly
andreaches equilibriumatahigherlevelwithinafewmicrosecondsfollowingexposure.6Dependingonthetypeofcell,an
increaseintransmembranepotential in the range of300mV
to1Vcanaectthestructureofthebilipidlayerformingthe
plasma membrane. e bilipid layer reorganizes in response
tothesuddenincreaseintransmembranepotential,resulting
intheformationofnano-scaleporesinthemembrane,which
caneventuallyleadtoIREofthecell.7PulseparametersdrivingcellIREcanbecharacterizedbytheamplitude(voltage)of
theexternalelectriceld,thelengthofexposure(pulselength),
the timing between consecutive exposures (pulse repetition
frequency), and groupingof exposure during delivery (pulse
train).Eachoftheseparametersindependentlycontributesto
theinductionofcell electroporation,andthereforehastobe
carefullyselectedtoachieveIRE,whileavoidingthenon-lethal
reversibleformofelectroporation.
Electric eld strength
e electric eld strength required toelevate the transmembranepotentialandinduceIREcanbedeterminedusingwhat
iscommonlyknownastheSchwannequation.etransmembranepotentialinducedatanylocationinthecell membrane
Interventional Oncology, Second Edition, ed. Jean-François H.Geschwind and Michael C.Soulen. Published by Cambridge University Press.
©Cambridge University Press2016
13

Section II:Principles of image-guided therapies
15 mm
Figure 3.1 (A) Computed tomography (CT) image of irreversible
electroporation (IRE) probe placement to treat recurrent tumor
(asterisk) adjacent to the rectum (arrowhead). (B) Magnetic
resonance imaging image of tumor (asterisk) near hepatic veins and
bile duct. (C) CT image showing IRE probe placement to treat the
tumor (asterisk).
equationitbecomesevidentthatlargercellswillundergoIRE
+
–+
atlowerelectriceld strengths thansmaller cells.Also,locationsinthecellthatdirectlyfaceorfallbetweentheelectrodes
will experience higher transmembrane potential than points
that are perpendicular to the electrodes. is equation was
developedundertheassumptionthatcellsroughlyhavesphericalshapewhensuspendedinmedia.Finiteelementmodeling
andnumericalsimulationcanbeusedtoestimatetransmembranepotentialofcellsunderin-vivoconditions.Cellsintissue
20 mm
aremoretightly packed thancellsuspensions,andtheexternalelectriceldcangetdistortedbythecellsandsurrounding
extracellular matrix.9 Under such conditions,the transmembranepotentialwillbehighestat the cell poles andlocations
orientedatfavorableanglestotheelectrodes.To successfully
induceIREinaspeciccelltype,considerationmustbegiven
Figure 3.2 Schematic showing minimum number of probes required and
resulting ablation zone. (A) Irreversible electroporation (IRE): the ablation
zone is mediated between two commercially available monopolar probes.
(B) Radiofrequency ablation (RFA): the ablation is centered on a single probe.
MWA = microwave ablation.
duetoanexternalelectriceldisafunctionoftheradiusofthe
cellandtheincludedanglebetweentheradiusandthepointat
whichthemembranepotentialisbeingevaluated.8Fromthis
IRE
RFA/MWA
totheapproximatesizedistributionofcellsbeingtreatedand
theexternalelectriceld strengthmustbe adjustedsuchthat
minimumtransmembranepotentialofapproximately0.7–1V
isachieved,eveninsmallercellsorcellsthatmaybeatanunfavorableorientationrelativetotheelectrodes.
Pulselength
Followingexposuretoanexternalelectriceldthetransmembranevoltageofacellexponentiallyincreasesbeforereachinga
14

Chapter3:Irreversible electroporation
(
)
( )
Figure 3.3 Computer simulation showing incomplete irreversible electroporation treatment zone (red) because: (A) improper choice of voltage for given probe
spacing results in inadequate ablation between probes (arrow); (B) unequal probe insertion resulting in ablation defect around one probe (arrow).
stablevalue.Forelectroporationtooccur,thetransmembrane
potential needs to reach such an equilibrium value and be
maintainedatthatpointforabriefperiodoftime(fewmicroseconds).
8,10
For an external electric eld of xed strength,
largercells will develophighertransmembranepotentialbut
take more time to achieve stable values when compared to
smallercellstreatedwithsimilarpulseparameters.Ifthelength
ofexposuretotheelectriceld(pulse length)issmallerthan
thechargingtimeofthecell,thenthetransmembranepotential may notreach a threshold sucient for electroporation.
Alternately,ifthepulselengthismuchlongerthanthechargingtimerequiredforachievingastabletransmembranepotential,theexcessenergy is dissipatedthroughJouleor resistive
heating.erefore,thepulselengthhastobeadjustedtoallow
transmembranepotentialtoreachcriticalthresholdinthecells
beingtreated,butatthesametimehastobekeptsmallenough
toavoidheating eects. Based on these considerations,pulse
length between 50 and100 μs has been reported to be optimalforinducingIREinhumancancercellswithoutsignicant
Jouleheatingeects.
Numerical simulations
e treatment eects of IRE under in-vivo conditions are
largelycontingentonthedistributionandintensityoftheelectriceldarisingfromapplicationofavoltagebetweenneedle
electrodes. e electric eld distribution can be mathematicallyevaluatedatdierentlocationsinthetissuebysolvingthe
Laplaceequationfortheappliedelectriceld
−∇ ∇
Fromthisequation,itbecomesevidentthatthemagnitudeof
electriceld(ϕ)strengthdevelopedinvivoisafunctionofthe
appliedexternalvoltage(ϕ=V0atthepositiveelectrode)and
the electrical conductivity(σ)of the tissue underconsideration.Tumorsandtheirsurroundingenvironmentcanbe heterogeneousatamacroscopiclevel,consistingofdierenttissue
types likeblood vessels, nerves, adipose tissue, bile duct, or
urinarycollectingsystem.Dierenttissuesinturnexhibitlarge
variationsin the electrical conductivity,andthereforeimpact
orinuencetheelectriceldstrengthdevelopedwithinthem.
Forexample,simulationsfromNealandDavalos15suggestthat,
despiteusingoptimalprobeplacementandtreatmentparameters,thedierenceinelectricalconductivitybetweentumor
.
σφ
=
0
.
and surrounding normal tissue mayultimatelyinuence the
Number ofpulses
Electroporationisacumulativeprocess,whererepeatedexposuretotheexternalelectriceldcontributestothetotalnumberandsizeofporesformedonthecellmembrane.eoretical
modelsimplyalogarithmicrelationbetweenamplitudeofthe
electric eld and the number of pulses required to achieve
electroporation.Othermodelssuggestthatcelldeaththrough
IREmay be considered a statisticalprocess,whereincreased
exposureandappliedvoltagein combinationaectcellsina
targetregioninanexponentialprocess.11Whilesomeofthese
theoretical models havebeen veried through in-vitrostudies,suchmodelsremainlargelyunveriedunderin-vivoconditions.However,it is widely acceptedthatapproximately10
pulsesaresucienttoinducereversibleorIRE intissuecontingenton the appliedeldstrength.Typically50–100pulses
mustbeappliedtoensurecellsinatargetvolumeoftissuehave
undergoneIRE.
12
successofablation(Figure3.4). Ben-Davidet al.suggestthat
locoregionalvariationsinelectricalconductivity,suchaswhat
isobservedneartherenalcollectingsystem,16canalsoimpact
thesizeandshapeofIREtreatmentzone when comparedto
ablationsperformed awayfrom such locations. Metallic elementssuchas stents,markerseeds,and ablationprobeswith
exposedtipsnotbeingusedfortreatmentmayalsopotentially
altertheablativeelectriceld.
DevelopingnumericalsimulationasareliabletoolforplanningIREtreatmentshasbeenaresearchchallenge.etypeof
tissuebeingtreated,thenumericalmodelemployed,andcorrelationwithpathology or imaging17all impact theaccuracy
andreliabilitywithwhich treatmentzones can be estimated.
Also,limitationsin nite element modeling necessitategross
representationoftissuetypesandproperties,andthereforeat
the current stage it is challenging to determine electric eld
distributionatsubmillimeterthresholds.Hence,theutilityof
13,14
15

Section II:Principles of image-guided therapies
asingleablationprobe.20However,mostofthesestudieshave
beencarriedoutin apreclinicalsettingtodemonstratefeasibility,andrequiresignicantecacyandsafetystudiesbefore
theycanbetranslatedforpatientuse.
Clinical considerations
Asanimage-guidedablationtechnique,thereisalackoftissue
samplesthatcanbeusedforperformingpathologyanalysisto
conrmtreatmentecacyfollowingIREoftumors.erefore,
itis crucial to identify imaging parametersand other physiologicalchangesthatwillserveassurrogateindicatorsoftreatment completion following IRE. A dramatic change in the
electricalconductivityofthetreatedtissueisalwaysobserved
duringandimmediatelyaerelectroporation.Inthe absence
ofotherindicators,thischangeinelectricalconductivityofthe
treatedtissuehasbeen consideredas a means for measuring
therelativeeectivenessofelectroporation.
21,22
Undernormal
conditions,biologicaltissueexhibitsanon-linearincreasein
Figure 3.4 Computer simulation of irreversible electroporation ablation of
tumor (circle; arrowhead) and ablation margin (arrow) when: (A) tumor has
higher electrical conductivity than surrounding tissue; (B) tumor has lower
electrical conductivity than surrounding tissue.
simulations for IRE treatment is restricted to gross estimationofexpectedelectricelddistributionandcannotberelied
uponforpredictionsofecacyatthecellularlevel.
Equipment and ablationprobes
IRE treatment requires the availability of a high-voltage
square-wave generator and suitable electrodes for delivering
direct current (DC) electric pulses into the target tissue. e
onlygeneratorcleared by the Food and DrugAdministration
(FDA)forso-tissueablationistheNanoknifelow-energyDC
electroporation device (Angiodynamics, Latham, NY). e
generatoriscapableofdeliveringamaximumof100pulsesata
time,withanamplitudeintherangeof500–3,000Vandofpulse
lengthintherangeof70–100μs. e generatordeliversthese
pulsesin groups of ten, with eachpulseseparatedby250 ms
andthepulsetrainsseparatedby3.5seconds.egeneratoris
capableofsupportingup to six ablation probesatatimeand
thepulsesaredeliveredusingECGsynchronization.esystem
comeswith19G(1mmdiameter)ablationprobesthatareavailablein15-cmlength.WhiletherearenootherFDA-approved
generatorsordevicesforpatientuse,systemssuchastheECM
830square-wavegenerator(BTX,HarvardApparatus)arecapableofenergyoutputequivalenttotheNanoknifeandareoen
usedinpreclinicalanimalmodelstudies.
Anumberofpreclinicalstudiesreport noveldevices that
extendtheuseofIREtoapplicationsotherthanpercutaneous
so-tissueablationusingneedleelectrodes.Maoretal.report
acatheterfortheIREofvascularsmoothmuscleinbloodvessels,18 Srimathveeravalli et al. report the development of an
endorectalprobeforfocal-transmuraltreatmentoftherectal
wall,19andNealet al. have reported a bipolar electrode congurationthatwouldallowso-tissueablationusingIREwith
electrical conductivityinresponsetoincreasingfrequencyat
which electrical current is applied. e maximum electrical
conductivityofthetissueisseenintheMHzfrequencyrange
orhigher.isispartlyduetothecomplexelectricalbehavior
ofcells,whichbehavesimilartoaresistor-capacitor(RC)circuitfunctioninginparalleltotheelectricallyconductivepath
providedbytheextracellularuid.Successfulelectroporation
ofthesecellscausestwoeects:thereleaseofintracellularuid
into the extracellular regions and the short-circuiting of the
normalRC circuit behavior of thecells.ese two eects in
combinationhave been observed to cause large increases in
tissue conductivity even at lower electrical frequencies. is
changeintheelectricalconductivityofthetreatedtissuecanbe
observedbothduringtheapplicationofeachpulseandinsum
totaloverthedurationoftreatmentdelivery.Nealetal.23have
investigatedthis eect foruseasasurrogatemarker forsuccessfulIREoftissueandhavereportedsomecorrelationwith
pathologyexaminationfollowingIREtreatmentofprostatein
2patients.Whileapromisingandusefultechnique,thecaveat
isthat,whilethemagnitudeofconductivitychangesisindicativeofIRE,itdoesnotquantifythetypeorvolumeoftissuethat
hasundergoneelectroporation.istechnique requiresmore
researchbeforeitcanbeconsideredforuseasastand-alone
indicatoroftheadequacyofIREablationinpatients.
Atthemoment,contrast-enhancedcomputedtomography
(CECT)andultrasound(US)aretheprimarytoolsforguiding
IREtreatment,andfortheconrmationofablationoutcomes
inpatients.On immediateposttreatmentCECT imaging, tissuetreatedwithIREappearsasahypodenseregionwithaconcentriczoneofenhancementoutsidetheablationborder.e
centralzonecorrelatestothenecroticcoreofthetreatedarea
andtheenhancingperipheryislikelytreatedtissuethatexperiencedreversibleelectroporationandhasdevelopedleakyblood
vessels(Figure3.5).esendingsaresimilartoobservations
commonly found during immediate posttreatment imaging
ndings, seen sometimes following radiofrequency ablation
ormicrowaveablation.However, incontrastto thermalablationtechniques,treatmentoftumorsintheliverusingIREis
16

Chapter3:Irreversible electroporation
believedtoresultinlesserdegreeofbrosisandscarformation. As a consequence, posttreatmentfollow-up imaging of
IRE-treatedtissueseemstoappearandevolvedierentlywhen
comparedtotumorstreatedwithradiofrequency ablationor
microwaveablation.We have observed that follow-up imagingofsuccessfullocalcontrolinpatientswhounderwentIRE
ablationof livermetastasisshowedinvolutionoftheablation
defect,withapproximately22%reductionatthe1-monthtime
pointandupto35%reductioninsizeat3months.isearly
evidenceneedsvericationinalargecontrolled studybefore
theevolutionoftheablationzonefollowingIREcanbeusedto
prognosticatetreatmentresponseatanearlystage.
IRE treatment can alter the echogenic properties of the
treated tissue and US imaging has been evaluated for the
real-time observation of ablationprogressand forimmediate
posttreatmentconrmationoftheablatedregion.
24,25
However,
resultsreportedintheliteraturewereobtainedfollowingIREof
normalporcineliveranduseof USimagingisyet toundergo
extensive evaluation for guiding and conrming ablation of
malignant tissue. e presence of the tumor may confound
or impact the resolution of US imaging ndings, and thereforereducetheacuitywithwhichitcanidentifychangesinthe
ablatedregion.IREofcellscauseslargereleaseofintracellular
uidintotheextracellularspace,andhasbeenobservedtodisrupt vascular ow within treated regions. ese eects have
beenusedtomapnormalbrain,26prostate(Figure3.6),kidney,27
andlivertumors28thatweretreatedusingIRE.Magneticresonanceimaging(MRI)hasprovenusefulfordelineatingregions
ablatedwithIREfromsurroundingregionsthatweretransiently
electroporated.esendingsarefrompreclinicalstudies,and,
asclinicalIREisnotMR-compatible,thelogisticsofusingMRI
forfollow-uponIREablationsperformedinpatientsmayprove
challenging.Inuorodeoxyglucose-avidlesions,positronemission tomography (PET)-CT guidance may prove useful for
guidingandfollowinguponIREablations.29UnlikeCTorMRI,
PETimagesthefunctionalstateofcellswithinthetreatedtissue
andthereforemayprovideaclearerpicturewithoutbeingconfoundedbymorphologicalchangesthatarenormallyobserved
followingIRE.Earlytrialsinpatients(Figure3.7)demonstrate
PET-CTtobeapromisingnewtechniqueforconrmingtreatmentadequacyintheimmediateposttreatmentsetting.
Clinical experience
ere is relatively limited clinical experience with IRE and
Figure 3.5 Contrast-enhanced computed tomography image taken
immediately following irreversible electroporation ablation of colorectal
metastasis (asterisk) in the liver. An enhancing rim is seen around the
treatment region (arrowhead).
most evidence of ecacy or safety is based upon reports of
small numbers of patients. A review article from Scheer
etal.30reports16publishedstudies,withatotalof221patients
and325tumorstreatedacrossallofthem.emajorportions
ofIREtreatmentswereperformedontumorsintheliver(129)
Figure 3.6 (A) Intraoperative ultrasound image with prostate and irreversible electroporation probes outlined. (B) Hypointense region corresponding to the
treatment zone seen on 3-month follow-up magnetic resonance imaging. (Courtesy of Dr. Jonathan Coleman.)
17

Section II:Principles of image-guided therapies
Figure 3.7 Positron emission tomography (PET)
imaging performed using split-dose technique.
(A) Tumor (arrowhead) on pretreatment image.
(B) Tumor (arrowhead) shows lack of enhancement
following ablation on immediate posttreatment
split-dose PET image.
andpancreas(69).Accordingtotheirreport,ecacyoftreatments in the liver ranged from 55% to 95% at the 6-month
follow-up time point, with limited complication prole.
ClinicalreportsfromCannonetal.,31Kinghametal.,2andSilk
etal.4clearlyindicatesafetyofapplicationofIREclosetobile
ductsandlargebloodvesselsfortreatmentoftumorsincentral
liver.Pneumothoraxandmildbileduct occlusionseemtobe
occasionalcomplicationsfollowingIRE oflesionsintheliver.
IREtreatmentofpancreatictumorsseemstobestowsurvival
benettopatientsaccordingtoreportsfromMartinetal.32and
Narayananetal.33Bileductleakageandportalveinthrombosis
representsignicantcomplicationsthatmaymanifestfollowingIREablationinthepancreas.Afewcasesofmildpancreatitishavealsobeenreported.
Conclusion
IREisapromisingnewclinicaltool thatissafetouse forthe
local management of tumors that are suitable for treatment
with established thermal ablation techniques. ere is some
evidenceofsafetyofapplyingIRE adjacentto sensitivestructuressuchasthebileduct.However,asanewtechnique,there
is limited knowledge for correctly directing IRE treatment
and assessing ablation ecacy with existing imaging tools.
erefore,physiciansusingIRE must educate themselves on
the biophysics of this treatment modality so that they may
choose appropriatetreatmentparametersthatwill maximize
benettopatientswhileminimizingtheriskprole.
References
1. FarojaM,AhmedM,AppelbaumL,etal.Irreversible
electroporationablation:isallthedamagenonthermal?
Radiology2013;266:462–470.
2. KinghamTP,KarkarAM,D’AngelicaMI,etal.Ablation
ofperivascularhepaticmalignanttumorswithirreversible
electroporation.Am Coll Surg2012;215(3):379–387.
3. PhillipsM,MaorE,RubinskyB.Nonthermalirreversible
electroporationfortissuedecellularization.J Biomech Eng2010;
132(9):091003.
4. SilkMT,WimmerT,LeeKS,etal.Percutaneousablationof
peribiliarytumorswithirreversibleelectroporation.J Vasc
Interv Radiol2014;25:112–118.
5. DeodharA,DickfeldT,SingleGW,etal.Irreversible
electroporationneartheheart:ventriculararrhythmiascan
bepreventedwithECGsynchronization.AJR Am J Roentgenol
2011;196(3):W330–W335.
6. WeaverJC.Electroporationtheory.Conceptsandmechanisms.
Methods Mol Biol1995;55:3–28.
7. ValicB,GolzioM,PavlinM,etal.Eectofelectriceldinduced
transmembranepotentialonspheroidalcells:theoryand
experiment.Eur Biophys J2003;32(6):519–528.
8. IvorraA.Tissueelectroporationasabioelectric
phenomenon:basicconcepts.InRubinskyB,ed.Irreversible
Electroporation.SpringerSeriesinBiomedicalEngineering.
Berlin:Springer,2010;pp.23–61.
9. GowrishankarTR,WeaverJC.Anapproachtoelectrical
modelingofsingleandmultiplecells.Proc Natl Acad Sci U S A.
2003;100(6):3203–3208.
10. HuiSW.Eectsofpulselengthandstrengthonelectroporation
eciency.Methods Mol Biol1995;55:29–40.
11. GolbergA,RubinskyB.Astatisticalmodelfor
multidimensionalirreversibleelectroporationcelldeathin
tissue.Biomed Eng Online2010;9:13.
12. RubinskyJ,OnikG,MikusP,etal.Optimalparametersforthe
destructionofprostatecancerusingirreversibleelectroporation.
J Urol2008;180(6):2668–2674.
13. DavalosRV,MirIL,RubinskyB.Tissueablationwith
irreversibleelectroporation.Ann Biomed Eng2005;33
(2):223–231.
14. DanielsC,RubinskyB.Electricaleldandtemperaturemodel
ofnonthermalirreversibleelectroporationinheterogeneous
tissues.J Biomech Eng2009;131(7):071006.
15. NealRE2nd,DavalosRV.efeasibilityofirreversible
electroporationforthetreatmentofbreastcancerand
otherheterogeneoussystems.Ann Biomed Eng2009;37
(12):2615–2625.
16. Ben-DavidE,AhmedM,FarojaM,etal.Irreversible
electroporation:treatmenteectissusceptibletolocal
environmentandtissueproperties.Radiology2013;269
(3):738–747.
17. WimmerT,SrimathveeravalliG,GuttaN,etal.Comparison
ofsimulation-basedtreatmentplanningwithimagingand
pathologyoutcomesforpercutaneousCT-guidedirreversible
electroporationoftheporcinepancreas:apilotstudy.J Vasc
Interv Radiol2013;24(11):1709–1718.
18. MaorE,IvorraA,MitchellJJ,etal.Vascularsmooth
musclecellsablationwithendovascularnonthermal
irreversibleelectroporation.J Vasc Interv Radiol2010;21
(11):1708–1715.
19. SrimathveeravalliG,WimmerT,MonetteS,etal.Evaluation
ofanendorectalelectrodeforperformingfocusedirreversible
electroporationablationsintheswinerectum.J Vasc Interv
Radiol2013;24(8):1249–1256.
18
Соседние файлы в папке Библиотека им академика М.И. Перельмана
